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Abstract
MicroRNAs (miRNAs), a class of small non-protein-encoding RNAs, regulate gene expression via suppression of
target mRNAs. MiRNAs are present in body fluids in a remarkable stable form as packaged in microvesicles of
endocytic origin, named exosomes. In the present study, we have assessed miRNA expression in urinary exosomes
from type 1 diabetic patients with and without incipient diabetic nephropathy. Results showed that miR-130a and
miR-145 were enriched, while miR-155 and miR-424 reduced in urinary exosomes from patients with
microalbuminuria. Similarly, in an animal model of early experimental diabetic nephropathy, urinary exosomal
miR-145 levels were increased and this was paralleled by miR-145 overexpression within the glomeruli. Exposure of
cultured mesangial cells to high glucose increased miR-145 content in both mesangial cells and mesangial cells-
derived exosomes, providing a potential mechanism for diabetes-induced miR-145 overexpression. In conclusion,
urinary exosomal miRNA content is altered in type 1 diabetic patients with incipient diabetic nephropathy and
miR-145 may represent a novel candidate biomarker/player in the complication.
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Introduction
Diabetic nephropathy (DN) is a major cause of renal
replacement therapy in the Western World. Microalbuminuria is
widely used as a biomarker for DN; however, its clinical
relevance as a surrogate outcome in chronic kidney disease
has not been confirmed and recent studies suggest that
microalbuminuria is a less precise predictor of nephropathy risk
than originally thought [1-3]. There is, thus, an increasing quest
to find novel biomarkers to identify and treat individuals at high
risk. In addition, early biomarker discovery may also help to
identify new players in the pathogenesis of the glomerular
injury in diabetes.
Urine is an ideal source of biomarkers for renal diseases [4]
and urinary mRNA profiling has been proposed as a tool for
biomarker discovery. However, urinary mRNAs are labile as
easily degraded by urinary RNase and they often originate from
apoptotic/necrotic cells with a scarcely representative
transcriptional profile [4]. Urine also contains cup-shaped
vesicles, known as exosomes, which derive from the cellular
endocytic compartment [5]. Exosomes carry RNAs that can
deliver to distant target cells and represent an important way of
cell-to-cell communication [6]. At variance with free urinary
RNAs, exosomal nucleic acids are in a remarkable stable form
as microvesicles protect them from endogenous RNase
activity. Furthermore, they derive from viable cells from all
nephron segments and may thus provide valuable insight on
renal pathophysiology [4].
Exosomes contain microRNA (miRNA), a class of small non-
protein-encoding RNAs that regulate gene expression via
suppression of target mRNAs [7]. Specifically, miRNAs bind
through canonical base pairing to a complementary site in the
3’ untranslated region of their target mRNAs and can direct the
degradation or translational repression of these transcripts [7].
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MiRNAs are critically involved in many biological processes
and accumulating evidence also points to an important role of
miRNAs in the pathogenesis of both diabetes and diabetes-
related complications [8,9]. Moreover, miRNAs, present in body
fluids, can display unique expression profiles in pathological
conditions and it has been proposed that distinctive miRNA
signatures may be exploited as innovative diagnostic/
prognostic tools [10-12]. Despite the growing interest in
miRNAs, urinary exosomal miRNAs have never been studied in
either normal or pathological conditions.
In this study, we have assessed miRNA expression in urinary
exosomes from type 1 diabetic patients (DM1) with and without
incipient DN. Furthermore, pathophysiological relevance of
miR-145, which was enriched in urinary exosomes from
microalbuminuric patients, was explored in both streptozotocin-
induced diabetic mice and cultured mesangial cells.
Materials and Methods
Materials
All materials were purchased from Sigma-Aldrich (St Louis,
USA) unless otherwise stated.
Subjects
The study was approved by the Ethical Committee of Turin
University, the procedures were in accordance with the Helsinki
Declaration, and informed written consent was obtained from
all subjects. Twelve DM1 with persistent microalbuminuria and
normal renal function and 12 normoalbuminuric DM1
comparable for age, sex, and diabetes duration were
consecutively enrolled in the study. Ten non-diabetic subjects
similar for demographic characteristics (age: 56.3 ± 2.8; sex:
10/0 M/F; hypertension Y/N: 5/5) served as control group.
Patients with cardiovascular diseases, non-diabetic kidney
diseases, or renal tract pathological conditions were excluded.
Microalbuminuria was defined as either an albumin excretion
rate (AER) value of 20-200 μg/min or an urinary albumin/
creatinine ratio (ACR) of 2.5-25 mg/mmol in males and 3.5-35
mg/mmol in females in two out of three overnight urine
collections. ACR values were converted in AER values using a
conversion formula previously developed in DM1 [13].
Hypertension was defined as systolic blood pressure >140
mmHg and/or diastolic blood pressure >90 mmHg or treatment
with antihypertensive drugs. Diabetic retinopathy was assessed
by direct funduscopic examination. Urinary albumin was
measured by nephelometry, urinary creatinine concentration by
the modified Jaffe method, and HbA1C by ion-exchange liquid
chromatography.
Urinary exosomes isolation
Overnight urine collections (~450 mL/subject) were obtained
from all recruited subjects. Urines were pre-cleared by both
centrifugation (300 g 10 min at 4 °C and 17,000 g 20 min at 4
°C) and filtration (0.8 μm) to remove cellular debris. Then,
exosomes were isolated by two consecutive ultracentrifugation
steps (200,000 g 75 min at 4 °C; 70.1 Ti rotor, Beckman
Instruments, Fullerton, CA) as previously described [14].
Pellets were suspended in phosphate buffer and exosome
quality and purity assessed by electron microscopy and
immunoblotting. Exosome quantity was determined by
measuring the rate of Brownian motion using a NanoSight
LM10 system, which is equipped with a fast video capture and
particle-tracking software (NanoSight Ltd, Wiltshire, UK). In
selected experiments, exosomes were treated with RNase A
(1U/ml, Fermentas, Glen Burnie, MD) prior to RNA extraction.
Immunoblotting
Pellets obtained after ultracentrifugation was dissolved in
100 μl of Laemmli buffer. Total protein concentration was
determined using the RC DC Protein Assay Kit (Bio-Rad,
Milan, Italy). Proteins (~70µg) were separated by SDS-PAGE
and transferred to nitrocellulose membranes (Amersham
Pharmacia, Freiburg, Germany). Following blocking,
membranes were incubated with primary antibodies against
Hsp70 (StressGen, Victoria, BC Canada), alix, or calnexin
(SantaCruz, Glostrup, Denmark) overnight at 4°C. After
washing, secondary HRP-linked (SantaCruz) antibodies were
added. Detection was performed using either the ECL
chemiluminescence substrate (Amersham) or the super signal
PICO/FEMTO (Euroclone, Milan, Italy) and visualised on a Gel-
Doc system (Bio-Rad, Milan, Italy). Total protein extracts from
mesangial, HeLa, and 293T cells were used as positive control
for Hsp70, alix, and calnexin, respectively. GAPDH was used
as loading control for calnexin.
Trasmission Electron Microscopy
Pellets resuspended in PBS were loaded onto formwar
carbon coated grids, fixed in 4% paraformaldehyde, and
washed. Microvesicles were post-fixed in 2.5% glutaraldehyde,
washed, contrasted in 2% uranyl acetate, embedded in a
mixture of uranyl acetate (0.8%) and methyl cellulose (0.13%),
and examined with a Philips CM 10 electron microscope.
Microphotographs were taken using a SIS Megaview II digital
camera.
Total RNA extraction and miRNA expression profiling
Total RNA was extracted using the Trizol reagent (Invitrogen,
Milan, Italy) and quantified by spectrophotometry (Nanodrop
ND-1000 Wilmington DE). On average 1-2 μg of total RNA
were obtained from each subject. RNA quality was assessed
by capillary electrophoresis on an Agilent-2100 Bioanalyzer
(Agilent Technologies, Santa Clara, CA). MiRNAs were reverse
transcribed using the Megaplex Primer Pool A, Human Pool A
v2.1 (Applied Biosystems), which contains RT primers for 377
miRNAs, 3 endogenous controls, and a negative control. RT
reaction products were pre-amplified using the Megaplex
PreAmp Primers (Primers A v2.1) and the TaqMan® PreAmp
Master Mix. MiRNA expression profile was performed in 2 pairs
of micro/normoalbuminuric DM1 patients tightly matched for
HbA1c (1st pair: 8.1 vs. 8.1, 2nd pair: 8.7 vs. 8.7) by Human
TaqMan miRNA Array A on an 7900HT Fast Real-Time PCR
System. Raw Ct values were calculated using the SDS
software and standardized to U6 snRNA. MiRNAs were
excluded if both samples within a pair had Ct values ≥ 35/
undetermined. Relative expression was calculated using the
Urinary Exosomal MicroRNAs and Microalbuminuria
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comparative Ct method (2-ΔΔCt). MiRNAs were considered
differentially expressed if they exhibited greater than twofold
expression differences in both pairs. Data are publicly available
at the NCBI Gene Expression Omnibus repository (accession
number: GSE48318). Interrogation of the www.microrna.org
database was performed to identify differentially expressed
miRNA known to be expressed by glomerular cells (in silico
analysis).
Taqman qPCR
Expression of a subset of miRNAs (miR-145, miR-424,
miR-155, miR-130a) was quantitated in both DM1 and control
subjects,using specific Taqman microRNA Assays. Diluted pre-
amplification products were combined with Taqman miRNA
Assay and Taqman Universal PCR Master Mix No AmpErase
UNG, then a qPCR was performed on an Applied Biosystems
7900HT thermocycler. All samples were run in triplicates and
standardized to U6 snRNA using the SDS2.2 software.
Animals and diabetes induction
The study was approved by the Ethical Committee of the
Turin University, and both housing and care of laboratory
animals were in accordance with Italian law (D.L.116/1992).
Male C57BL6/J mice from Jackson Laboratories (Bar Harbor,
ME) were maintained on a normal diet under standard animal
house conditions. Diabetes was induced by intraperitoneal
injection of streptozotocin (55 mg/kg body wt/day), delivered in
five consecutive daily doses. Mice that were sham injected with
sodium citrate buffer were used as controls. Diabetes onset
was confirmed by blood glucose levels >250 mg/dL 4 weeks
after the first dose of STZ. Animals were killed ten weeks after
diabetes onset. Prior to sacrifice, blood samples were taken via
saphenous vein puncture on alert 4-hours–fasted animals and
urine collected. Glucose levels were measured using a
glucometer (Roche, Milan, Italy) and glycated hemoglobin by
quantitative immunoturbidimetric latex determination (Sentinel
Diagnostic, Milan, Italy).
Urine collections and exosomal isolation
Urine was collected over 18 hours, with each mouse
individually housed in a metabolic cage and provided with food
and water ad libitum. Urinary albumin concentration was
measured by a mouse albumin ELISA kit (Bethyl Laboratories,
Milan, Italy). Urinary exosomes were isolated from pooled urine
from both diabetic and non-diabetic mice (n=30 per group) as
described above.
Glomerular isolation.  Both non-diabetic (n=5) and diabetic
(n=5) mice were anesthetized and perfused with 8x107 surface-
inactivated Dynabeads (Invitrogen, Milan, Italy), the glomeruli
were isolated using a modified Takemoto et al method [15,16].
Glomerular and urinary exosomal miR-145 expression
Total RNA was extracted from both urinary exosomes and
isolated glomeruli of diabetic and control mice using the Trizol
reagent, then miR-145 expression quantitated by Taqman qRT-
PCR as described above.
Mesangial Cell Culture
Cultures of immortalised human mesangial cells were
established and characterized as previously described [17].
Cells were cultured in Dulbecco’s Modified Eagle’s Medium
(Invitrogen, Milan, Italy), containing L-glutamine, 6.8 mM
glucose, 20% exosomes-depleted foetal calf serum (FCS,
Euroclone Milan, Italy) (17), 100 U/ml penicillin, and 100 µg/ml
streptomycin in a humidified 5% CO2 incubator at 37°C.
Mesangial Cell Transfection of miR-145
Mesangial cells were transfected with either a pre-miR-145
precursor (Life Technology) or a negative control using
Lipofectamine 2000 (Invitrogen). After 24 hours, cells were
lysed and STAT-1 protein expression by immunoblotting using
a specific rabbit anti-STAT-1 antibody (Cell Signalling, Milan,
Italy). Tubulin was used as loading control.
Mesangial Cell Exposure to High Glucose
Concentration
After serum deprivation for 24 hours, human mesangial cells
were exposed to increasing (6.8 mM, 15 mM, and 25 mM)
glucose concentrations for various time period (4, 6, 12, and 24
hours). Media were made iso-osmolar with the addition of
mannitol. Total RNA was extracted and miR-145 levels
measured as described above. At the 24 hours time point
mesangial cell supernatants were also collected and exosomes
isolated by differential centrifugations. Briefly, supernatants
were centrifuged at 300 g for 10 min then at 20,000 g for 20
min, followed by filtration through a 0.22 µm filter. Exosomes
were then pelleted by ultracentrifugation at 120,000g for 70 min
and total RNA extracted for miR-145 measurement as
described above. An aliquot of the exosomal preparation was
used for exosome counting by NanoSight LM10 system
followed by normalization to total cell number.
Data presentation and statistical analysis
Data were expressed either as mean ± SEM or as geometric
mean (25th-75th percentile). Results were analyzed by t test or
ANOVA, as appropriate. Variables with skewed distribution
were analyzed after logarithmic transformation. Values for
P<0.05 were considered statistically significant.
Results
Patients characteristics
Clinical and laboratory characteristics of recruited subjects
are shown in Table 1. Micro- and normoalbuminuric patients
were comparable for age, sex, diabetes duration, and renal
function. HbA1c values were greater in micro- than in
normoalbuminuric patients, but this did not reach statistical
significance. As expected, AER was higher in patients with
incipient DN than in normoalbuminuric subjects.
Characterization of urinary exosomes
Vesicles, isolated from overnight urine collections, were <100
nm in size and showed a characteristic cup-shaped
morphology at the electron microscopy (Figure S1A).
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Immunoblotting analysis demonstrated expression of both
Hsp70 and alix, which are well-established exosomal markers
[18]. On the contrary, vesicles were negative for calnexin, an
endoplasmatic reticulum protein, confirming the absence of
contamination from other cellular compartments (Figure S1B).
Exosome quantity in overnight urine collections was similar
in diabetic patients [335 x 108 (303-562), geometric mean
(25th-75th percentile)] as compared to controls [251 x 108
(128-700)], a reduction in urinary exosome number was
observed in microalbuminuric DM1 [175 x 108 (112-245)],
though this did not reach statistical significance.
Urinary exosomes contains small RNA
Total RNA, extracted from isolated exosomes, was analyzed
on an Agilent 2100 Bioanalyzer and the resulting
electropherogram showed that urinary exosomes were
enriched in small RNA species, including miRNAs, but did not
contain ribosomal RNA (Figure S1C). RNA was confined within
exosomes as it was still found when intact microvesicles were
pre-treated with RNase (Figure S1D).
MiR-130a, miR-424, miR-155, miR-145 are differentially
expressed in urinary exosomes from microalbuminuric
DM1
Two hundred and twenty six miRNAs were detectable in the
urinary exosomes from normoalbuminuric DM1 patients.
Differential miRNA profiling showed that expression of 22
miRNAs differed in both matched pairs of micro/
normoalbuminuric patients. Out of them 4 miRNAs were
chosen for further analysis by qRT-PCR in all recruited
subjects. MiR-130a, miR-424, miR-155 were selected as they
are expressed by cultured human podocytes
(www.microrna.org); miR-145 was chosen because is a known
marker of glomerular mesangial cells (19,20). Consistent with
profiling results, qRT-PCR analysis showed that miR-155 and
miR-424 levels were significantly lower, while miR-130a and
miR-145 levels significantly higher in micro- than in
normoalbuminuric patients. MiR-155 and miR-424 were similar
in normoalbuminuric diabetic patients and non-diabetic
Table 1. Clinical and Laboratory Parameters of Type 1
Diabetic Patients.
 Normoalbuminuric DM1 Microalbuminuric DM1
N 12 12
Age (years) 57.9 ± 3.7 58.0 ± 2.7
Sex (male/female) 12/0 12/0
Diabetes duration (years) 33.8 ± 3.5 30.7 ± 2.8
HbA1C (%) 7.8 ± 0.3 8.2 ± 0.3
Serum creatinine (mg/dl) 0.8 ± 0.02 0.9 ± 0.04
Retinopathy (y/n) 8/4 12/0
Hypertension (y/n) 7/5 7/5
AER (μg/min) 8.00 (6.62-7.67) 72.30 (62.18-89.90)*
Data are means ± SEM; DM1: type 1 diabetic patients, AER: albumin excretion
rate; *p<0.001 microalbuminuric vs normoalbuminuric patients.
doi: 10.1371/journal.pone.0073798.t001
controls, while levels of miR-145 and miR-130 were greater in
normoalbuminuric diabetic patients than in controls, though this
did not reach statistical significance (Table 2).
Previous studies in mesangial cells have shown that
miR-145 is a target of TGF-β1 (21), a prosclerotic cytokine
playing a key role in diabetic nephropathy; therefore, this
miRNA was chosen for subsequent both in vivo and in vitro
studies.
Urinary exosomes from diabetic mice are enriched for
miR-145
After 10 weeks of STZ-induced diabetes, both blood glucose
and glycated hemoglobin levels were significantly higher in
diabetic than in non-diabetic mice. Furthermore, compared with
sham-injected control animals, diabetic mice showed a
significant rise in albumin excretion rate (Table 3). Urinary
exosomes were isolated from pooled urine from both diabetic
and non-diabetic mice and miR-145 levels measured by qRT-
PCR. Results showed that miR-145 levels were twice higher in
diabetic than in non-diabetic animals (Figure 1A), indicating
that urinary exosomes have a greater miR-145 content not only
in human, but also in experimental DN.
miR-145 is overexpressed in the glomeruli from
diabetic mice
To investigate if enhanced urinary exosomal miR-145 levels
mirror a parallel change within the glomeruli, we studied
miR-145 expression in glomeruli isolated from both diabetic
and control mice. As shown in Figure 1B, miR-145 was weakly
expressed in the glomeruli from non-diabetic mice, but highly
expressed in the glomeruli from diabetic mice. Quantitatively,
diabetic animals showed a significant nine-fold increase in
glomerular miR-145 levels.
Table 2. MiR-130a, miR-424, miR-155, miR-145 content in
urinary exosomes from diabetic patients and non-diabetic
control subjects.
 
Non-diabetic
Controls
Normoalbuminuric
DM1
Microalbuminuric
DM1
miR-145 0.66(0.26-1.73) 1.14 (0.73-1.71) 3.11 (2.09-5.10)*#
miR-130a 0.44(0.27-1.32) 0.91 (0.49-1.81) 2.54 (2.30-3.47)*#
miR-155 2.38(1.45-3.15) 1.90 (1.22-2.54) 0.79 (0.39-1.82)*°
miR-424 2.58(2.49-3.13) 2.22 (1.74-3.26) 1.05 (0.80-2.31)§#
Data are shown as geometric mean (25th-75th percentile). *p<0.01; §p<0.05
microalbuminuric diabetic patients vs non-diabetic controls. ° p<0.01; #p<0.05
micro- vs normoalbuminuric diabetic patients.
doi: 10.1371/journal.pone.0073798.t002
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Exposure to high glucose induces miR-145 expression
in cultured mesangial cells
Having established that diabetes induces glomerular
miR-145 expression, we investigated the underlying cellular
mechanism in vitro in mesangial cells. Hyperglycaemia is a key
determinant in the pathogenesis of DN; therefore, we assessed
if exposure to high glucose affected miR-145 expression in
mesangial cells. MiR-145 was expressed by mesangial cells
cultured in a normal glucose milieu. Furthermore, miR-145 was
functionally active in this cell type as miR-145 transfection
suppressed STAT-1 protein expression modestly, but
significantly (Figure 2A). Exposure to both 15 and 25 mM
glucose concentrations for 4 hours induced a significant three-
fold rise in miR-145 levels and this effect was sustained up to
24 hours, suggesting that hyperglycemia may be implicated in
glomerular miR-145 overexpression in diabetic mice (Figure
2B).
Table 3. General assessment parameters in diabetic and
non-diabetic mice.
 Non-Diabetic Diabetic
N 30 30
Body weight (g) 28.9 ± 0.41 24.9 ± 0.40*
Blood Glucose (mg/dl) 107.6 ± 4.21 347.5 ± 16.7*
Glycated Hb (%) 4.5 ± 0.12 11.6 ± 0.32*
Systolic BP (mmHg) 118 ± 2.98 120 ± 3.60
AER (μg/18h) 76.5 (60.4-89.2) 322.7 (218.9-348.1)*
Data are shown as mean ± SEM or geometric mean (25th-75th percentile). BP:
blood pressure; AER: albumin excretion rate; *p<0.001 diabetic vs. non-diabetic
mice.
doi: 10.1371/journal.pone.0073798.t003
Figure 1.  Expression of miR-145 in experimental
diabetes.  MiR-145 levels were measured by qRT-PCR in both
urinary exosomes (A) and isolated glomeruli (B) from diabetic
(DM) and control (ND) mice as described in the Methods.
Results, corrected for the expression of housekeeping U6
snRNA, are shown in the graphs (*p<0.001 DM vs ND).
doi: 10.1371/journal.pone.0073798.g001
MiR-145 is enhanced in exosomes released by
mesangial cell exposed to high glucose
To clarify if high glucose exposure also affects exosomal
miR-145 content, exosomes were isolated from the
supernatants of mesangial cells exposed for 24 hours to either
high or normal glucose concentrations. Exposure to high
glucose reduced the quantity of exosomes released by
mesangial cells [NG: 1.28 107/100000 cells (1.06-1.49)
geometric mean (25th-75th percentile); HG: 0.59 x
107(0.58-0.60), p<0.05 NG vs HG], but significant enhanced
exosomal miR-145 content (Figure 2C). Moreover, the high
glucose-induced rise in exosomal miR-145 levels was
comparable in magnitude to that observed in parent mesangial
cells.
Figure 2.  Expression of miR-145 in human mesangial
cells.  (A) Expression of STAT-1, a known miR-145 target, was
assessed by immunoblotting in total protein extracts from
mesangial cells transfected with either miR-145 mimic or
scramble oligonucleotides. Tubulin was used as loading
control. Results are depicted in the graph (*p<0.05) and a
representative immunoblot is shown. (B) Human mesangial
cells were exposed to increasing (6.8, 15, and 25 mM) glucose
concentrations for 4,6,12 and 24 hours. Total RNA was
extracted and levels of miR-145 measured by qRT-PCR
(*p<0.01) 15 and 25 mM glucose vs. 6.8 mM glucose at all time
points). (C) Human mesangial cells were exposed to either
normal (6.8 mM-NG) or high (25 mM-HG) glucose
concentrations for 24 hours. Exosomes were isolated from the
supernatants by ultracentrifugation as described in the
Methods. Total RNA was extracted and levels of miR-145
measured by qRT-PCR (*p<0.001 HG vs. NG).
doi: 10.1371/journal.pone.0073798.g002
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Discussion
This study provides the first evidence that urinary exosomes
contain a vast array of miRNAs. Urinary exosomes were
obtained by a two-step differential ultracentrifugation process
that is regarded as the gold standard method for exosomal
isolation from biological fluids, including urine [14]. This method
allows efficient isolation of exosomes with a high degree of
purity, though it is laborious and time-consuming. Other larger
types of vesicles may co-isolate with exosomes using most
isolation methods; however, larger vesicles are unlikely to
contribute significantly to our findings as isolated microvesicles
were positive for specific exosomal markers and displayed both
the size and shape characteristic of exosomes at the electron
microscopy.
MiRNA expression profiling revealed a differential exosomal
miRNA expression in two pairs of tightly matched micro/
normoalbuminuric DM1 patients. Although these results are
preliminary, they provide a proof of concept of the feasibility of
this novel approach for biomarker discovery. Further studies
are warranted to establish whether a distinctive urinary
exosomal miRNA signature exists in DN and may be exploited
as diagnostic/prognostic tool. It is noteworthy in this regard that
our patients had low degree of microalbuminuria and normal
renal function, suggesting that abnormalities in urinary
exosomal miRNA expression may occur in an early stage of
the disease.
In diabetic patients with microalbuminuria there was also a
trend toward a reduction in urinary exosome quantity. Although
the difference did not reach statistical significance, this finding
may be of potential relevance and worth of further
investigations in larger series of patients as exosome count
may represent an additional aspect of the potential use of
exosome as DN biomarker.
A recent paper by Argyropoulos C et al has reported
changes of urinary miRNA spectrum in DM1 patients with
different stages of albuminuria and nephropathy [22].
Differentially expressed miRNAs identified in this report do not
overlap with those found in our study. This is, however, not
surprising because Argyropoulos C et al. compared urine
miRNAs from DM1 patients with persistent and intermittent
microalbuminuria and profiled total urinary miRNAs rather than
exosomal miRNAs. Although total urine miRNA profiling is
easier to perform and less time-consuming with consequent
advantages for translation in clinical practise, the analysis of
exosomal urinary miRNAs is likely to be more accurate as total
urine miRNAs can also originate from apoptotic/necrotic cells
facing the urinary tract. In addition, as plasma miRNAs have a
small molecular weight and can pass the glomerular filtration
barrier, a substantial portion of total urine miRNAs is likely of
plasma rather than of renal origin and this diminishes the
relevance of total urinary miRNA analysis for biomarker
discovery in renal pathophysiology.
Our profiling results did not reveal significant difference in
miR-192 expression between micro and normoalbuminuric
DM1 patients, though miR-192 has been implicated in the
pathogenesis of DN and is induced by TGF-β1 in mesangial
cells [23]. Opposing modulation of miR-192 in mesangial cells
[23] and tubular epithelial cells in DN [24], resulting in an
overall null effect on urinary miRNA levels may be a potential
explanation. Alternatively, we cannot exclude the possibility
that cells overexpressing miR-192 release exosomes with
normal miR-192 content as exosomes carry exclusively
miRNAs that need to be deliver to distant target cells.
Validation of profiling results in all recruited patients
confirmed that urinary exosomal miR-145 levels were
significantly enhanced in microalbuminuric as compared to
normoalbuminuric DM1 patients and control non-diabetic
subjects. This finding is of potential pathophysiological
relevance as miR-145 is a glomerular marker of mesangial
cells [20] and is induced by TGF-β1 in this cell type [21]. In
keeping with this hypothesis, our in vivo study showed that
miR-145 levels were increased in both the urinary exosomes
and the glomeruli isolated from streptozotocin-induced diabetic
mice. This is the first report of glomerular miR-145
overexpression in an experimental model of DN and together
with previous studies, reporting altered miRNA expression in
DN [25,26], support the hypothesis of a miRNA involvement in
the development of the complication.
In vitro in cultured mesangial cells miR-145 was expressed
and functionally active as its overexpression resulted in
suppression of STAT-1, a known miR-145 target [27].
Exposure to high glucose induced a rapid and sustained
increase in miR-145 expression in human mesangial cells,
suggesting hyperglycaemia as a possible insult inducing
glomerular miR-145 overexpression. TGF-β1 is a likely
mediator because high glucose is a well established TGF-β1
inducer in mesangial cells [28] and TGF-β1 rises miR-145
expression in both mesangial [21] and vascular smooth muscle
cells through a SMAD-dependent pathway [29]. Recent studies
in vascular muscle cells have proven that miR-145 is a key
determinant in the switching from a proliferative to a
differentiated/contractile phenotype [19,30], raising the
hypothesis of a miR-145 role in high glucose-induced
mesangial cell both hypertrophy and cytoskeleton remodelling.
In diabetic mice, glomerular miR-145 overexpression was
paralleled by an increase in urinary exosomal miR-145 content.
In addition, mesangial cell exposure to high glucose induced
the release of exosomes enriched in miR-145, mirroring the
overexpression observed in parent cells. This raises the
attractive possibility of a mesangial cell origin of urinary
exosomes carrying enhanced miR-145 content. Although
exosome size is over the cut-off value for glomerular filtration, a
recent study has proven that exosomes can cross physiological
barriers, such as the brain blood barrier [31]. The underlying
mechanism is unclear; however, a process of transcytosis,
possibly through the multivesicular bodies (MVB) compartment,
has been proposed [32,33].
In various cell types exosome release is enhanced by
cellular stresses [34]; however, in our study the quantity of
exosomes released by mesangial cells exposed to high
glucose, a known inducer of oxidative stress, was significantly
diminished and could not account for the rise in miR-145 levels.
The underlying mechanism is unknown; however, it is tempting
to speculate that high glucose may interfere in the complex
process leading to exosome formation/release from the MVB.
Urinary Exosomal MicroRNAs and Microalbuminuria
PLOS ONE | www.plosone.org 6 November 2013 | Volume 8 | Issue 11 | e73798
Although our in vivo and in vitro work points to
hyperglycaemia as a likely miR-145 inducer; HbA1c levels
were similar in DM1 with and without microalbuminuria and do
not justify the greater miR-145 exosomal content seen in
patients with incipient DN. However, we cannot exclude the
possibility that serum glucose levels differ in the two groups at
the time of urine sampling. In addition, in the microalbuminuric
group greater blood glucose fluctuation in the period prior to
sampling and/or enhanced formation of advance glycation end-
products/TGF-β1 may provide explanation for a glucose-
dependent effect despite similar HbA1c levels. Finally, patients
in the microalbuminuric group are likely to have experienced in
the past poor metabolic control and a metabolic memory-
related effect cannot be rule out. Consistent with the
hypothesis of a glucose-related effect, miR-145 values were
also enhanced in the urinary exosomes from normoalbuminuric
DM1 patients as compared to controls, though this did not
reached statistical significance.
Urinary exosomal miR-130a was also up-regulated in DM1
patients and further increased in subjects with
microalbuminuria. On the contrary, miR-155 and miR-424 were
downregulated and this effect was observed specifically in DM1
with incipient DN. These miRNAs are known to be expressed,
though not exclusively, by podocytes and podocyte-derived
exosomes can be easily found into urine as this cell type faces
the urinary space. Of interest, recent studies have shown that
miR-155 and miR-424 negatively modulate the signalling of
cytokines, such as angiotensin II [35,36], TGF-β1 [37,38], and
VEGF [39], that play a key role in the pathogenesis of DN.
Whether changes in the urinary exosomal content of miR-130a,
miR-155, miR-424 mirror parallel changes in parent cells
remains, however, to be established.
In conclusion, in this study we have identified miR-145 as a
new potential player in diabetic glomerulopathy and
demonstrated the feasibility of the study of urinary exosomal
miRNA for candidate biomarker discovery in diabetic and other
renal diseases. Further studies on larger series of patients are
warranted to confirm our findings and assess their clinical
relevance.
Supporting Information
Figure S1.  Identification and characterisation of
exosomes. (A) Urinary exosomes were isolated from overnight
urine collections by differential ultracentrifugation as describe in
the Methods. Urinary vesicles, showing the characteristic
exosomal cup-shape and size, are shown in the representative
electron micrograph; scale bar = 200nm. (B) Expression of
both exosomal (Hsp70, alix) and endoplasmatic reticulum
(calnexin) specific markers was assessed by immunoblotting in
total protein extracts from isolated urinary exosomes and
positive controls (MC: mesangial cells). GAPDH was used as
loading control for calnexin. Representative immunoblots are
shown. Total RNA, extracted from urinary exosomes, was
analyzed on an Agilent 2100 Bioanalyzer using either a RNA
6000 Pico Kit (C) or a small RNA kit (D). The representative
electropherogram shows that urinary exosomes contain small
RNA species (<150 nt), including microRNAs (10-40 nt).
(TIF)
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